Frontiers in Oncology (Aug 2022)

FN1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers

  • Han Wang,
  • Han Wang,
  • Junchang Zhang,
  • Junchang Zhang,
  • Huan Li,
  • Huan Li,
  • Hong Yu,
  • Songyao Chen,
  • Songyao Chen,
  • Shuhao Liu,
  • Shuhao Liu,
  • Changhua Zhang,
  • Yulong He,
  • Yulong He

DOI
https://doi.org/10.3389/fonc.2022.918719
Journal volume & issue
Vol. 12

Abstract

Read online

Fibronectin 1 (FN1) is a glycoprotein found throughout the extracellular matrix that has a role in the onset and progression of cancer. However, its immune relationship with gastric cancer is still unclear. FN1 was systematically reviewed by Gene Expression Profiling Interactive Analysis (GEPIA), Linked Omics, Tumor IMmune Estimation Resource (TIMER), and Kaplan–Meier (KM) plotter analysis. The TIMER, GEPIA, TISIDB, and cBioPortal databases investigated the association of FN1 with tumor immune infiltration and validated using immunohistochemistry. We discovered that tumor tissue expresses FN1 at a higher level than neighboring tissue, and those genes coexpressed with FN1 have a poor prognosis. At the same time, we discovered that increased FN1 expression was related to immunological infiltration, particularly macrophage infiltration. Using immunohistochemistry, we discovered that FN1 expression was tightly connected to M2 macrophages. It can be concluded that FN1 can affect the immunological microenvironment and is a prognostic marker in gastric cancer.

Keywords